Racura Oncology Ltd (ASX: RAC) Share Price and News

Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She was the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT). Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentech's commercial division. Dr Baldwin's experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech's early stage oncology programs. Dr Baldwin currently serves on the boards of Anaxis Pharma,Gertrude Biomedical, and AusBiotech. Other Directorships held include Invex Therapeutics (from 1 February 2021 to 30 June 2024).

Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private Australian biotechnology company producing and selling DNA sequencing software to the genomics industry. Nucleics SAAS (software as a service) genomics tools are used in more than 30 countries and at over 250 companies and research institutions. Dr Tillett was previously an Executive Director and Chief Scientific Officer at Race from 17 September 2019 and 1 October 2019, respectively and resigned from both roles on 21 March 2023. Dr Tillett was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, virology, microbiology, bioinformatics and cancer. He has more than 40 scientific publications and granted patents in molecular biology, virology, microbiology, genetics and biochemistry. Other Directorships include Simble Solutions Limited (Non Executive Director appointed 16 February 2022, resigned 3 July 2023); Tryptamine Therapeutics Limited (Non-Executive Director, appointed 8 November 2024).

Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies and drug approval. He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-founded and was Chief Financial Officer of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ initial public offerings, fundraisings, and M&A. He is also currently a Director of Amala Therapeutics.

Dr Scrofani has more than 28 years' experience in the healthcare sector, working in global roles across research and strategy, and corporate and business development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives including the company's global COVID-19 response and its $US11.7 billion acquisition of Vifor Pharma AG. Prior to this, he led Business Development for subsidiary CSL Behring, based in the United States (US). Serge is currently CEO and Managing Director of FinCap Group Holdings Pty Ltd, an Australian private investment firm. He is also a Board member of the Burnet Institute and The Centre for Eye Research. Serge undertook postdoctoral research studies at The University of Melbourne and completed a Fulbright postdoctoral fellowship at The Scripps Research Institute, La Jolla California.

-

-